Authors:
Setnikar, I
Schmid, K
Rovati, LC
Vens-Cappell, B
Mazur, D
Kozak, I
Citation: I. Setnikar et al., Bioavailability and pharmacokinetic profile of dihydroergotoxine from a tablet and from an oral solution formulation, ARZNEI-FOR, 51(1), 2001, pp. 2-6
Authors:
Wangemann, M
Retzow, A
Mazur, D
Vens-Cappell, B
Citation: M. Wangemann et al., Study on the dose proportionality of the pharmacokinetics of sustained release sodium valproate, INT J CL PH, 38(8), 2000, pp. 395-401
Authors:
Retzow, A
Althaus, M
de Mey, C
Mazur, D
Vens-Cappell, B
Citation: A. Retzow et al., Study on the interaction of the dopamine agonist alpha-dihydroergocryptinewith the pharmacokinetics of digoxin, ARZNEI-FOR, 50(7), 2000, pp. 591-596
Authors:
Mazur, D
Schug, BS
Evers, G
Larsimont, V
Fieger-Buschges, H
Gimbel, W
Keilbach-Bermann, A
Blume, HH
Citation: D. Mazur et al., Bioavailability and selected pharmacokinetic parameters of clindamycin hydrochloride after administration of a new 600 mg tablet formulation, INT J CL PH, 37(8), 1999, pp. 386-392
Citation: W. Ferenc et al., Spectral and thermal studies of light lanthanide complexes with 4-methoxy-3-nitrobenzoic acid, CROAT CHEM, 72(4), 1999, pp. 779-787
Authors:
Wangemann, M
Retzow, A
Evers, G
Mazur, D
Schug, B
Blume, H
Citation: M. Wangemann et al., Bioavailability study of two carbamazepine containing sustained release formulations after multiple oral dose administration, ARZNEI-FOR, 48(12), 1998, pp. 1131-1137